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ABSTRACT
Epithelial-to-mesenchymal transition (EMT) has been implicated in the 
progression of bladder cancer.  To study its contribution to bladder cancer metastasis, 
we established new xenograft models derived from human bladder cancer cell lines 
utilizing an orthotopic "recycling" technique that allowed us to isolate and examine 
the primary tumor and its corresponding circulating tumor cells (CTC’s) and metastatic 
lesions.  Using whole genome mRNA expression profiling, we found that a reversible 
epithelial-to-mesenchymal transition (EMT) characterized by TGFβ pathway activation 
and SNAIL expression was associated with the accumulation of CTCs.  Finally, we 
observed that conditional silencing of SNAIL completely blocked CTC production and 
regional/distant metastasis.  Using this unique bladder cancer xenograft model, we 
conclude that metastasis is dependent on a reversible EMT mediated by SNAIL. 
INTRODUCTION
Bladder cancer (BC) poses a significant health 
concern to the global community [1] and once it becomes 
metastatic, patients have uniformly fatal outcomes. 
Despite this, only one advance in treatment for metastatic 
bladder cancer beyond cisplatin-based chemotherapy 
(atezolizumab [2]) has been made over the past few 
decades [3, 4].  The molecular mechanisms mediating 
BC metastasis are still poorly defined [5–8] providing the 
opportunity to translate new biologic insights into novel 
effective strategies for this disease. 
Epithelial-to-mesenchymal transition (EMT) is a 
reversible cellular process occurring in epithelial tissues, 
whereby homotypic adhesion and cellular polarity are 
transiently lost as cells adopt mesenchymal properties 
and become invasive and migratory [9].  These events are 
driven by transforming growth factor-beta (TGFβ) and 
other microenvironmental stimuli that downregulate the 
prototypic epithelial adhesion molecule, E-cadherin, and 
upregulate several transcriptional repressors of E-cadherin, 
including ZEB1/2, SNAIL, Slug, and Twist [9].  Recent 
studies employing preclinical models representing 
squamous cell carcinoma [10] and breast cancer [5, 6, 
9, 11, 12] have established that EMT is necessary for 
metastasis.  The reverse process–“mesenchymal to 
epithelial transition”, or MET–may also play an important 
role in cancer metastasis [13].  Proliferation and invasion/
migration may be mutually exclusive processes (cells 
do not proliferate while they are moving) [14–16], so 
there is possibly a growth advantage for tumor cells in 
the “epithelial” state. EMT has been linked to invasive 
BC [17–20], but its role in BC metastasis is largely 
unconfirmed. 
In this study, we established two new murine models 
of metastatic BC through orthotopic recycling [21] and 
used a whole genome approach to characterize the changes 
in the expression of genes involved in EMT that occurred 
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at critical points during metastasis.  We observed that while 
both primary tumor cells and metastatic lesions shared 
epithelial markers and morphology, circulating tumor cells 
(CTC’s) were distinctive and displayed a mesenchymal 
genotype, represented by the increased expression of the 
transcription factor SNAIL.  Furthermore, with conditional 
silencing of SNAIL, CTC production and regional/distant 
metastasis were suppressed, and then reestablished 
when SNAIL expression was restored.  These findings 
support the hypothesis that transcription factors such as 
SNAIL promote EMT and mediate the transition to a 
mesenchymal phenotype in CTC’s, which is necessary for 
BC cells to spread to distant sites.
RESULTS
Recycling of mesenchymal cell lines leads to 
increased epithelial gene co-expression and a 
spontaneously metastatic xenograft model
E-cadherin and ZEB1 were expressed in a non-
overlapping fashion in human BC cell lines [17], creating 
two distinct subgroups, “epithelial” (high E-cadherin, low 
ZEB1) and “mesenchymal” (low E-Cadherin, high ZEB1). 
Based on RT-PCR data, we classified these cell lines 
accordingly: UM-UC3 and UM-UC13 as “mesenchymal” 
and UM-UC6, UM-UC9, and UM-UC14 as “epithelial” 
(Figure 1).  These cell lines were then stably transduced 
with the reporter vector (luc-RFP), sorted by FACS, and 
injected orthotopically into athymic nude mice.  
The “epithelial” cell lines were highly tumorigenic 
but infrequently metastatic; lymph node (LN) metastases 
were only rarely identified by in vivo bioluminescence 
imaging even after recycling LN deposits (Table 1). 
Orthotopically implanted parental “mesenchymal” cells 
(UM-UC3 and UM-UC13) were initially less tumorigenic 
than the “epithelial” cell lines. After serial in vivo passaging 
(thereby selecting for the most proliferative tumor cells), 
the tumorigenicity of mesenchymal cell lines became 
similar to the epithelial lines. After the first orthotopic 
recycling, some mice developed LN and distant lung and 
bone metastases (Table 1).  We recovered LN metastases 
and re-injected them into the bladder, and after 3 passages, 
metastases developed in most mice once primary tumors 
were established (Table 1). In all BC xenograft models, 
the latency period required for establishing tumors with a 
photon count of 1 × 1010 decreased significantly after the 
first cycle of orthotopic growth (Table 1). 
CTC counts correlate with mesenchymal 
primary tumor and metastatic burden
We used quantitative RT-PCR (using human HLA-C 
specific primers) and FACS to quantify the burden of 
CTCs in whole blood isolated from mice bearing recycled 
UM-UC3 or UM-UC13 tumors (Figure 2A–2C). There 
was a strong correlation between the results obtained 
by the two methods (Spearman r = 0.984, p < 0.001; 
Figure 2D), with FACS providing the advantage of 
enabling simultaneous isolation and purification of CTCs 
for further characterization.  
Xenografts from both “mesenchymal” cell lines 
produced large numbers of CTCs that tended to form 
clusters (Figure 3A) [22], and the relative burden of CTCs 
correlated directly with the sizes of the corresponding 
primary tumors and with metastatic burden (Figure 3B). 
Of note, no CTCs were isolated from the 3 “epithelial” 
human BC xenografts.  Our findings establish that the 
presence of CTC’s is associated with BC metastasis, just 
as they are in other solid tumors [10, 23, 24].
CTCs have a transient mesenchymal expression 
profile that is lost in established metastasis
We compared the whole genome mRNA expression 
profiles of primary bladder tumors, LN metastases, distant 
metastases, and CTCs isolated from mice bearing the 
recycled UM-UC3 xenografts.  In order to understand 
unique aspects of CTC biology, we assessed the 
differentially expressed genes (FDR < 0.05, p < 0.001) 
between CTCs and other tissues (primary tumors, lymph 
node metastases, and distant metastases) using the class 
comparison tool within BRB array tools (Figure 4A, 
Supplementary Table S1).  
WebGestalt (Figure 4B–4C, Figure 5) pathway 
analysis identified TGFβ and adherens KEGG pathway 
targets in the CTCs and the primary tumors/metastases 
respectively. Downstream targets of TGFβ signaling (ID2, 
ID3, PPP2R1B, SMAD6, SMAD7) were significantly 
enriched in CTCs (Figure 4B, Figure 5A), suggesting 
that the TGFβ pathway activation was associated with the 
EMT pattern observed in the CTCs [25, 26].  Conversely, 
adherens junction genes were down-regulated in the CTCs 
compared to primary tumors and metastatic deposits 
(Figure 4C, Figure 5B). CTCs also demonstrated low 
SPARCL1 expression, a feature that has been associated 
with metastasis in prostate cancer [27].
Results of quantitative RT-PCR indicated that the 
CTCs were enriched for EMT biomarkers compared with 
the other tissue sources. Specifically, UM-UC3 CTCs 
expressed higher levels of mesenchymal transcription 
factors and lower levels of the epithelial markers E-cadherin 
and plakoglobin (JUP) [18] than did the primary tumors or 
metastases (Figure 6A).  Furthermore, we confirmed that 
the degree of EMT in CTCs, as represented by SNAIL 
overexpression, was enhanced through the selection process 
of orthotopic recycling (Figure 6B).  Using quantitative RT-
PCR, we also confirmed that the CTCs originating from 
the second recycled “mesenchymal” cell line - UM-UC13 - 
expressed much higher levels of mesenchymal transcription 
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factors SNAIL and Slug and lower levels of the epithelial 
markers E-cadherin and plakoglobin (JUP) (Figure 6C). 
RT-PCR results (SNAIL and E-Cadherin) were confirmed 
by Western blots (Figure 6D) and cell suspension staining 
of CTCs (Figure 6E).
SNAIL mediates BC metastasis
Whole genome mRNA expression profiling, 
quantitative RT-PCR, and single cell/tissue staining 
revealed that SNAIL (Snai1) seemed to play a key role 
Table 1: orthotopic recycling of bladder cancer cell lines
Cycle Mice Inoculated (n)
Successful Bladder 
Grafting (n)
Median progression 
time to large tumor (1010 
photon count) (weeks)
Mice with LN 
Metastasis (n)
Mice with Distant 
Metastasis (n)
UM-UC9
1 2 2 (100%) 14 0 0
2 5 4 (80%) 10 0 0
3 4 4 (100%) 5 1 (25%)* 0
4 16 15 (94%) 5 0 0
UM-UC6
1 2 2 (100%) 12 0 0
2 8 8 (100%) 10 0 0
3 3 3 (100%) 4 0 0
4 3 3 (100%) 5 0 0
UM-UC14
1 3 3 (100%) 11 0 0
2 3 3 (100%) 8 0 0
3 2 2 (100%) 3 0 0
4 16 15 (94%) 3 2 (13%)* 1 (6%)*
5 5 5 (100%) 4 0 0
6 5 5 (100%) 4 0 0
7 8 7 (88%) 3 1 (13%)* 0
8 20 20 (100%) 3 1 (5%)* 0
UM-UC3
1 5 2 (40%) 10 0 0
2 5 3 (60%) 9 2 (40%)* 1 (20%)*
3 5 5 (100%) 6 5 (100%)* 4 (80%)*
4 5 4 (80%) 5 4 (80%)* 4 (80%)*
5 3 2 (67%) 3 2 (67%)* 2 (67%)*
6 15 13 (87%) 3 12 (80%)* 5 (33%)*
7 20 20 (100%) 3 18 (90%)* 9 (45%)*
8 18 17 (94%) 4 15 (83%) 10 (56%)
UM-UC13
1 5 2 (40%) 16 0 0
2 5 4 (80%) 9 3 (60%)* 3 (60%)*
3 2 2 (100%) 5 2 (100%)* 1 (50%)*
4 2 2 (100%) 6 2 (100%) 2 (50%)
Labeled (luciferase and red fluorescent protein) human BC cell lines were orthotopically recycled according to previously 
published methodology.  Growth became more aggressive with successive generations (cycles).  The cell lines UM-UC3 
and UM-13 are characteristically mesenchymal, and their propensity for metastasis increased with successive recycling.
*In case of lymph node or distant metastases cell suspension was performed from metastases.
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in the process of EMT. Thus, we first stably transduced 
the recycled UM-UC3 cells with a shRNA lentiviral 
vector (GIPZ shRNA) and a non-targeting vector. 
SNAIL knockdown was confirmed in vitro using rtPCR 
and immunoblotting (Figure 7A) and in vivo with 
rtPCR (Figure 7B).  Inactivation of SNAIL resulted in a 
significant decrease in CTCs compared to non-targeting 
vector (Figure 7C). There was no significant change in 
primary tumor growth (Figure 7D). 
In order to overcome the problem of a possible 
off-target effect of the shRNA, we used a RNAi-based, 
doxycycline inducible lentiviral vector (TRIPZ shRNAmir, 
Tet-On®) targeting SNAIL to transduce recycled UM-
UC3 cells (SNAIL iKD). We confirmed the efficacy of the 
(on/off) vector function in vitro with a dose response curve 
at the mRNA and protein level (Figure 8A).  The primary 
tumors became more “epithelial” and less “mesenchymal” 
after doxycycline induced SNAIL knockdown as shown by 
the complementary downregulation of the “mesenchymal” 
markers SLUG and ZEB1 in vivo. (Figure 8B).
Recycled UM-UC3 cells transduced with the 
SNAIL iKD vector were then used for a randomized 
2-arm experiment. Inactivation of SNAIL via systemic 
doxycycline administration resulted in a significant 
decrease in CTCs and metastases compared to vehicle 
controls but no significant change in primary tumor 
growth (Figure 9A–9B). To evaluate for possible off target 
effects of doxycycline administration on tumor metastases, 
we administered doxycycline in the same manner to mice 
with orthotopic tumors from non-transfected recycled 
UM- UC3 cells, and no inhibitory effect on tumor 
metastasis could be demonstrated.  No metastases were 
detectable by in vivo bioluminescence imaging within 
7 days of tumor implantation in both the UM-UC3 and 
UM-UC13 metastatic models (representative results 
for UM-UC3 SNAIL iKD in Figure 9A).  Therefore, 
an experimental “window” appeared to exist between 
orthotopic tumor implantation and the establishment of 
spontaneous metastases that allowed for experimental 
manipulations directed at testing the roles of particular 
genetic changes in the process.  
We performed a 3-arm experiment (n = 15 to 20 mice 
per arm; Figure 10A) to determine if metastasis formation 
regulated by SNAIL is reversible.  After establishing UM-
Figure 1: In vivo characterization of human bladder cancer (BC) cell lines. Relative mRNA expression of labeled (luciferase 
and RFP) and fingerprinted cell lines grown in vitro prior to the first orthotopic inoculation. UM-UC3 and UM-UC13 BC cells are 
mesenchymal-like and showed high mRNA expression of ZEB1 and low expression of E-Cadherin compared to UM-UC6, UM-UC9, UM-
UC14 BC cell lines, which are more epithelial-like. 
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UC3 SNAIL iKD primary tumors, mice in the doxycycline 
and “switch” group were given doxycycline by oral gavage 
(25 mg/kg/d), and control animals were gavaged with vehicle 
only. Following treatment day 12, mice in the switch group 
were administered vehicle control, thereby restoring SNAIL 
expression by the primary tumors, seen in IHC staining 
(Figure 10A). We then compared the rates of primary 
tumor growth, tumor cell dissemination (CTCs), and the 
emergence of metastases. Again there were no differences 
in primary tumor growth among the groups (Figure 10B). 
None of the mice with sustained SNAIL knockdown 
(‘doxycycline’ group) developed metastases, whereas 
87% of mice in the vehicle control group had metastases 
by week 4 (Figure 10C).  Mice in the switch group only 
developed metastases after cessation of the doxycycline-
induced SNAIL knockdown (Figure 10C).  Consistent with 
their higher metastatic burden, more mice in the control 
group died before the planned end of the experiment at 
4 weeks.  Restoration of SNAIL expression in the switch 
group (Figure 10D) was also associated with a higher death 
rate in those mice. Finally, we observed the same patterns 
when we analyzed the CTCs, which were detectable prior 
to the establishment of distant metastasis.  Few CTCs were 
present in the mice treated continuously with doxycycline, 
whereas mice in the control group developed significantly 
more CTCs, and mice in the switch group developed CTCs 
once doxycycline administration was stopped (Figure 10E). 
Collectively, these experiments clearly demonstrate that 
SNAIL expression is transiently induced in CTCs and is 
critical for spontaneous metastasis in human BC xenografts.
DISCUSSION
Despite its relevance, there are actually very few 
preclinical models available for interrogating spontaneous 
bladder cancer metastasis.  The Fidler group pioneered 
many of the existing models using “orthotopic recycling” 
[21, 28, 29], whereby human cancer cells are implanted 
into their native organ microenvironment promoting the 
transition to a more “epithelial” phenotype and enhanced 
primary tumor growth.  Metastases are subsequently 
harvested and re-implanted into the orthotopic site to 
enrich the spontaneous metastatic phenotype. This process 
is repeated until essentially all mice develop metastases 
Figure 2: RT-PCR and FACS are effective methods of quantifying CTCs. (A–B) Standard curves for RT-PCR quantification 
for UM-UC3 and UM-UC13 CTCs, respectively. (C) FACS plot showing identification of the CTC population (originating from UM-UC3 
orthotopic tumors) in serum samples. Only the CTCs with the “strongest” signal were selected for further recycling. (D) Strong correlation 
(Spearman’s rho = 0.984) of UM-UC3 CTC quantification between RT-PCR and FACS methods. 
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after a shorter latency period. Using this approach we 
isolated metastatic variants of the human 253J cell line 
that reproducibly metastasized to lymph nodes (253J B-V, 
recycled 5 times) or lung (253J L-IV, recycled 4 times) over 
20 years ago [21]. Other groups have used intravenous 
inoculation of tumor cells to circumvent the need for 
spontaneous tumor cell extravasation [30, 31].  Intravenous 
injection-based  experimental metastasis models, however, 
bypass two crucial biological steps, namely an epithelial-
to-mesenchymal transition (EMT) that promotes invasion 
and the acquisition of circulating tumor cells (CTCs), and 
the reverse process (mesenchymal-to-epithelial transition, 
MET) at distant sites generating micrometastases [32, 33]. 
Early preclinical studies established that metastases 
arise from distinct sub-clones present within the primary 
tumor [7, 8, 34].  Because metastasis involves many 
different cell traits, it was proposed that clonal evolution 
selected for mutations that promoted each of the properties 
in sequence [35].  Our results and that of others [9–12] 
argue that reversible changes involving EMT (and as a 
consequence MET) are critically important for metastasis, 
challenging the notion that the metastatic phenotype is 
Figure 3: CTC correlates with primary and metastatic tumor burden in UM-UC3 and UM-UC13 xenografts. 
(A) Fluorescence microscopy of blood smear originating from UM-UC3 xenografts.  UM-UC3 cells are RFP-labeled.  Magnification 40×. 
CTCs are seen as single cell and clumps. (B) Correlation of primary tumor size to metastasis, primary tumor size to CTCs, and metastasis 
to CTCs in UM-UC3 and UM-UC13 xenografts.
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genetically hard-wired into cancer cells [21, 34], but 
rather that there is a central role for “plasticity” in 
metastasis. The recent implication of EMT in both stem 
cell biology and solid tumor metastasis provides one clear 
example of this biological plasticity [23, 36].
A comparison of the gene expression profiles 
between matched primary tumors, CTCs, and metastasis 
did not reveal dramatic differences in global gene 
expression among primary tumors and their metastases, 
but found a significantly different gene expression pattern 
in CTCs characterized by TGFβ pathway activation and 
EMT genes.  Inhibiting EMT in our model system via 
inducible knockdown of SNAIL completely blocked 
CTC production and metastasis, whereas restoration 
of SNAIL activated both.  These results complement 
contemporary reports that CTCs are more “mesenchymal” 
than matched primary tumors or metastases [22, 37, 
38], and that activation of Twist-1, which similarly 
represses E-Cadherin, also enabled cancer cells to enter 
the circulation, while subsequent down-regulation of 
Twist1 accompanied growth at metastatic sites using a 
carcinogen-induced rodent model [10]. There is now 
accumulating evidence that EMT is promoted by tumor-
host interactions [13]. Labelle et al reported that platelet 
derived TGFβ was sufficient to promote metastasis, while 
silencing TGFβ-1 inhibited the process [39].  CTCs from 
breast cancer patients formed aggregates with platelets 
and displayed evidence of TGFβ pathway activation [23], 
which is consistent with our observation that UM-UC3 
CTC’s were clustered on the blood smear and expressed 
downstream mediators of TGFβ signaling. 
Recent evidence suggests that, in a genetically 
engineered pancreatic cancer and lung cancer murine 
models, EMT underlies chemoresistance but is not linked 
to metastasis [40, 41]. The different findings in these 
reports and our studies is unknown but may be related to 
Figure 4: Bladder cancer CTCs are characterized by TGFβ pathway activation and loss of adherens junction gene 
expression.  Whole genome mRNA expression profiling was performed on primary tumors, CTCs, and metastases. (A) Heatmap of the 
top differentially expressed genes (FDR < 0.05, p < 0.001) between CTCs and others cancer-involved tissues. (B) Expression of TGFβ 
pathway targets in the KEGG pathway (p < 0.05). (C) Expression of adherens junction genes in KEGG pathway (p < 0.05).
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Figure 5: Pathway analysis of differentially expressed genes.  WebGestalt was used to analyze the expression profile to find 
patterns that matched known KEGG signaling pathways. (A) TGFβ pathway targets (B) Adherens junction genes.
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Figure 6: Expression of “epithelial” and “mesenchymal” markers in vitro and in vivo. (A) Comparison of “epithelial” markers 
(left panel) and “mesenchymal” markers (right panel) for UM-UC3 in vitro (2D culture) and in vivo after the 3rd generation of recycling. 
Gene expression by the primary tumor, CTCs, lymph node (LN) metastases, and distant metastases were characterized by qRT-PCR. 
(B) Relative mRNA expression of SNAIL in UM-UC3 following successive orthotopic tumor recycling.  CTCs demonstrate increasing 
SNAIL expression with successive generations. (C) Comparison of “epithelial” markers (left panel) and “mesenchymal” markers (right 
panel) for UM-UC13 in vitro (2D culture) and in vivo after the 3rd generation of recycling using qRT-PCR. (D) Immunoblots for SNAIL 
and E-Cadherin of 2D culture cells, primary tumors, and metastases. (E) Cell suspension staining (GFP) for SNAIL in CTCs originating 
from mice with UM-UC3 orthotopic tumors which are luc-RFP labelled. 
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Figure 7: Stable SNAIL knockdown in vitro and in vivo. (A) UM-UC3 cells were transduced with SNAIL shRNA (KD) and 
non-targeting control (NT). Stable knockdown was confirmed by qRT-PCR and Immunoblot analysis in vitro. (B) Confirmation of stable 
knockdown of SNAIL in UM-UC3 primary tumors using qRT-PCR. (C) The effect of stable SNAIL knockdown on CTC formation (n = 6–8 
mice per group). (D) No effect of stable SNAIL knockdown on primary tumor growth could be demonstrated (n = 6–8 mice per group).
Figure 8: Inducible SNAIL inhibition results in other mesenchymal marker downregulation. (A) Knockdown efficacy 
of the RNAi (TRIPZ shRNAmir, Tet-On®) transduced UM-UC3 cells (recycled from LN metastases) following puromycin selection 
and induction with doxycycline at different concentrations in vitro. qRT-PCR (top) and Immunoblot analysis (bottom). (B) qRT-PCR 
demonstrating decreased expression of SLUG and ZEB1 in primary tumors after doxycycline treatment (25 mg/kg per day); 2 primary 
tumors of mice treated with doxycycline (treatment 1 and 2) were compared to 2 primary tumors of control mice (drinking water only; 
control 1 and 2).
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different metastatic mechanisms among different tumor 
types, or differences in the model systems (genetically 
engineered conditional knockouts versus orthotopic 
xenografts with targeted knockdowns). Notably, even 
more recent evidence has linked SNAIL-mediated EMT 
and metastasis across multiple tumor types: hepatocellular 
carcinoma (SNAIL mediated EMT) [42, 43], breast cancer 
[44], osteosarcoma [45], and pancreatic cancer (SNAIL-
mediated EMT) [46].
Since up to 40% of patients who undergo 
radical cystectomy with curative intent develop distant 
metastases [47–49], the early detection of CTCs is of 
Figure 9: Blocking SNAIL substantially inhibited metastasis and CTC formation but not primary tumor growth. 
(A) The effect of SNAIL silencing on primary tumor growth, formation of metastasis, and CTC counts at the completion of the experiment 
(Treatment Day 33).  Control versus a doxycycline-induced SNAIL knockdown arm. (B) CTCs were assessed in blood collected from a 
terminal cardiac puncture (Mean ± SEM) and were significantly inhibited following SNAIL knockdown.
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utmost relevance. Past studies employing CellSearch® 
which relies on antibodies to surface Ep-CAM to isolate 
CTCs yielded inconsistent results in patients with BC 
[50–52]. We now attribute this to our observation that 
Ep-CAM is restricted exclusively to human BC cells that 
display an “epithelial” phenotype whereas the CTCs in most 
preclinical metastatic models are clearly “mesenchymal”. 
Fortunately, great progress is being made in the advent of 
novel technologies to detect CTCs and associated circulating 
tumor DNA [53–55]. As these new platforms become 
commercially available, incorporating CTC metrics into 
routine clinical management may become possible. 
Relevant preclinical models are essential to 
understand the mechanisms regulating metastasis. In this 
study we developed new orthotopic models to investigate 
the role of EMT in BC metastasis. Despite the limitations 
of orthopic xenografts [56], using this approach we 
demonstrated the role of SNAIL in mediating a reversible 
EMT in BC metastasis. These results are reminiscent of 
conclusions drawn from the investigation of metastasis 
Figure 10: Inducible knocking down of SNAIL affects CTC and metastasis formation. (A) Schematic of the 3-arm UM-UC3 
SNAIL knockdown experiment with IHC staining for the “switch” group. After transduction in vitro, cells were orthotopically injected and 
primary tumors were grown for 2 weeks. Cells from primary tumors were isolated and inoculated in 50 mice. Mice were randomized into 
one of three arms (15 to 20 mice per arm). Primary tumors were established for 5 days at which point treatment commenced.  The control 
arm received water and tumors expressed SNAIL (vehicle, no doxycycline).  The mice in the treatment arm received doxycycline for 
24 days continuously, knocking down SNAIL for the entirety.  To assess the effect of delayed reactivation of SNAIL, mice in the “switch” 
group were given doxycycline until Day 12 at which point the doxycycline treatment was stopped.  (B) Growth of primary tumors (p = 0.99) 
(C) Metastasis in the 3 treatment groups by photon count and percent of mice with metastasis (p < 0.0001). (D) Kaplan-Meier survival 
curves of the 3 different treatment groups demonstrates more favorable survival in those mice with inhibited SNAIL expression (log-rank 
test: p = 0.001). (E) Blood was procured for CTC quantification by tail vein aspiration (Treatment Days 7, 12, and 19) and by terminal 
cardiac puncture (Day 24).  CTC counts were graphically compared (Mean ± SEM).  
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in carcinogen-induced murine models, which highlights 
the importance of employing appropriate animal models 
to study bladder cancer. Though SNAIL is implicated 
in MET as a function of correlative expression data, to 
fully understand bladder cancer metastasis, future work 
employing inducible “on” systems of candidate MET 
regulators will be informative; as such work may generate 
models that generate CTCs without the ability to establish 
distinct metastases.
In conclusion, SNAIL-mediated EMT appears to 
be a requirement for human bladder cancer metastasis, 
particularly as cancer cells leave the primary and enter 
systemic circulation prior to establishing metastatic 
deposits. While SNAIL modulation did not alter primary 
tumor growth, its link to metastasis suggests a stage-
specific therapeutic role for a SNAIL-targeting strategy 
in advanced, high-risk bladder cancer to prevent initial 
metastasis or progressive disease.
MATERIALS AND METHODS
Tissue and cell lines
Cell lines were provided by the M.D. Anderson 
Cancer Center Bladder SPORE Cell Line Repository 
and authenticated using the AmpFlSTR® Identifiler® 
Amplification (Applied Biosystems) and PCR 
Amplification (Applied Biosystems) kits.  Cell lines were 
maintained as previously described [17].
Animal protocol
Female athymic nude mice were purchased from 
National Cancer Institute (NCI-Frederick). The mice 
were housed and maintained under specific pathogen-
free conditions in facilities approved by the American 
Association for Accreditation of Laboratory Animal Care 
and in accordance with current regulations and standards 
of the United States Department of Agriculture, United 
States Department of Health and Human Services. 
This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. 
The protocol was approved by the University of Texas 
M. D. Anderson Cancer Center Animal Care and Use 
Committee (IACUC #110012735). 
All invasive procedures were performed under 
inhalational anesthesia using 3% Isoflurane (Piramal 
Enterprises Ltd, India) in aseptic conditions.  The mice 
were monitored daily, including weekends and holidays, 
with euthanasia performed using CO
2
 in the event of 
any of the following: tumor greater than 1.5 cm, > 20% 
weight loss, lethargy, inability to obtain food and/or water, 
labored breathing, hunched posture, abdominal distension 
equivalent to a pregnant mouse, or incapacitated as a result 
of tumor growth.
Orthotopic recycling
Human BC cells (UM-UC3, UM-UC-6, UM-UC-9, 
UM-UC13, and UM-UC-14) were transduced with a 
lentiviral reporter vector (TRIPZ shRNAmir, Tet-On®) 
encoding luciferase (luc) and red fluorescent protein 
(RFP; mCherry) and adding Polybrene (Santa Cruz, TX) to 
increase transfection efficiency.  After stable transfection of 
the luc-RFP reporter, cells were sorted by FACS using the 
Influx high-speed cell sorter (BD Biosciences). Luciferase 
activity was quantified by adding D-luciferin (150 μg/mL) 
to cell cultures and luminescence was measured using the 
IVIS bioluminescence system (Xenogen Co.)  
To produce tumors in nude mice, sub-confluent 
cultures of labeled cells were harvested with trypsin, 
mixed with 10% FBS MEM, centrifuged at 1,200 rpm for 
5 min, washed in PBS, and re-suspended in HBSS. After 
anesthesia induction, a low midline laparotomy incision 
was made and 5 × 105 cells in 50 μL solution were then 
implanted orthotopically into the bladder wall using a 
30 gauge needle.  Mice were sacrificed when they became 
moribund, whole blood was drawn via cardiac puncture 
(1–1.5 ml/mouse), tumors and/or metastases were excised, 
minced, exposed to 1% trypsin, centrifuged (1,200 rpm 
for 5 min), and cultured in 10% FBS MEM.  In this way, 
cells were recycled in female nude mice as described [17, 
21] (Table 1).  Mice were sacrificed when threshold tumor 
burden was appreciated, and tissue samples were either 
formalin fixed and embedded in paraffin, embedded in 
Tissue-Tek OCT compound (Sakura Finetek), or frozen 
rapidly in liquid nitrogen and stored at –80°C for RNA 
and protein extraction. Blood samples were put on ice and 
immediately processed as described below.
In vivo bioluminescence imaging
Bioluminescence imaging was conducted on an 
IVIS 100 imaging system with Living Image software 
(Xenogen) as previously described [16].  In brief, animals 
were anesthetized before imaging in a chamber containing 
a 2.5% isoflurane/O
2
 mixture and injected subcutaneously 
with 15 mg/mL of luciferin potassium salt in PBS at a 
dose of 150 mg/kg body weight. 12 minutes after luciferin 
injection, a digital gray-scale animal image was then 
overlaid with a pseudocolored image representing the spatial 
distribution of detected photons emerging from active 
luciferase.  Signal intensity was quantified as the sum of 
all detected photons within the region of interest, separately 
counting each primary tumor and each metastatic site.
Immunohistochemistry 
Xenograft tissue was embedded in Tissue-Tek OCT 
and then sections of primary tumor and metastasis were 
cut and blocked with 3% H
2
O
2
 in PBS, 5% horse, and 1% 
goat serum.  We used rabbit anti-E-Cadherin (Ab40772 
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Abcam; 1:50) and anti-SNAIL (ab135708 Abcam; 1:50) 
as primary antibodies and HRP conjugated goat anti-rabbit 
antibody (BioRad; 1:100) for the secondary antibody. 
After DAB incubation, slides were counterstained 
with hematoxylin.  Images were collected using Nikon 
Microphot FXA and compared to H&E stained sections 
processed in a conventional fashion.
Measurement and isolation of CTCs
Blood was collected via cardiac puncture as a 
terminal procedure under deep anesthesia in heparin-coated 
collection tubes at 4oC.  For further blood processing, the 
blood was divided into 2 aliquots, and red blood cells were 
lysed with 1 ml Ammonium-Chloride-Potassium (ACK) 
Lysing buffer (Invitrogen), and spun down to a pellet. 
The first pellet was lysed and total RNA was isolated for 
further Real-time Polymerase Chain Reaction (RT-PCR) 
analysis using absolute quantification to generate cycle 
threshold (C
T
) values for human specific HLA-C primer 
(Hs00740298_g1).  RT-PCR analysis (in triplicate) was 
run together with standard isolates (0, 2, 20, 200, 2000, and 
20,000 UM-UC3 cells in 100 μl mouse blood).  C
T
 values 
of the standards were used to create a standard curve for 
UM- UC3 CTC, and the total number of CTC’s of each 
whole blood sample was calculated accordingly.  The 
other pellet was re-suspended and CTCs were counted and 
isolated using FACS using red fluorescent protein (RFP; 
mCherry) as the discriminating marker.  The FACS isolated 
CTC pellet was finally stored at –80°C for RNA and protein 
extraction.  We DNA fingerprinted the CTC’s from both 
models and confirmed that the isolated cells were genetically 
identical to the parental UM-UC3 and UM-UC13 cells.
Staining of CTCs and single cell suspension from 
tissue
Blood was obtained from tumor-bearing mice under 
anesthesia using cardiac puncture as a terminal procedure. 
Red blood cells were lysed as described, the pellet was 
re-suspended in 2% FBS MEM, RFP labeled tumor cells 
(CTCs) were isolated using FACS and transferred on 
24-well plates. Cells were then washed with PBS, fixed 
with 4% paraformaldehyde, and stained with rabbit anti-
SNAIL (GeneTex GTX100754) or anti E-Cadherin (Cell 
Signaling #3195; Thermo Scientific # 710161) antibodies, 
followed by rabbit specific Alexa Fluor® 488 secondary 
antibody.  Immunofluorescence images were collected 
using Olympus IX81 microscope.
Silencing with stable (shRNA) and inducible 
(shRNAi) short hairpin RNA 
For shRNA based knockdown, recycled UM-UC3 
cells (5th cycle) were plated in two 6-well plates (105 cells/
well) and both plates were transfected 24 hours later with 
the lentiviral vector of interest (GIPZ lentiviral shRNA 
V3LHS_328730-2; TRIPZ shRNAmir, Tet-On®) and a 
non-targeting (NT) vector, respectively.  After puromycin 
selection (5 μg/ml), total RNA and protein lysates 
were collected to confirm efficacy of knockdown using 
quantitative RT-PCR and immunoblotting. For shRNAmir-
based knockdown, shRNAi expression was induced by 
doxycycline (Sigma) (1–10 μg/mL) before cell lysis.  
SNAIL shRNA in vivo experiments
To demonstrate the effect of SNAIL expression, 
recycled and transduced UM-UC3 SNAIL KD cells were 
orthotopically injected at a concentration of 105 cells in 
50 μL HBBS.  For the 2-arm stable knockdown versus 
NT vector experiment, mice (6–8 per group) were imaged 
after 14 and 28 days. For the 2-arm inducible SNAIL 
knockdown experiment, nude mice were randomized after 
orthotopic injection to receive either vehicle (drinking 
water; 250 μl/day; ‘control’ group’, n = 15) or doxycycline 
(Sigma; 25 mg/kg per day; ‘treatment’ group’, n = 20) 
by oral gavage.  Mice were imaged every 3–4 days, as 
described in “in vivo bioluminescence imaging” above, 
for 33 days.  At the end of the experiment, CTC’s were 
collected by cardiac puncture in both experiments before 
mice were sacrificed, as previously described.
To demonstrate the effect of reversible SNAIL 
expression, recycled and transduced UM-UC3 SNAIL iKD 
cells were orthotopically injected at a concentration of 105 
cells/50 μL in 50 mice.  In a 3-arm model (n = 15–20 for 
each arm), after establishing primary tumors, mice in the 
doxycycline and “switch” group were given doxycycline 
by oral gavage (25 mg/kg/d), and control animals were 
gavaged with vehicle only. Following treatment day 12, 
mice in the switch group were administered vehicle 
control, thereby restoring SNAIL expression by the 
primary tumors. We then compared the rates of primary 
tumor growth, tumor cell dissemination (CTCs), and the 
emergence of metastases. Tail vein blood (50–100 μl) 
was collected weekly to measure CTCs.  At the end of 
the experiment, CTC’s were collected by cardiac puncture 
before mice were sacrificed.
Gene expression profiling analysis
After RNA isolation, purity and integrity were 
measured using the NanoDrop ND1000 spectrophotometer 
and the Agilent Bioanalyzer electrophoresis system, 
respectively.  High quality RNA was then used for the 
synthesis of biotin-labeled cRNA using the Illumina RNA 
amplification kit (Ambion) as described previously [57]. 
Briefly, 500 ng total RNA was converted to cRNA by 
in vitro transcription, and then purified 1.5 μg cRNA was 
hybridized to Illumina HT12 v4 (Illumina) chip.  The slides 
from Direct Hybridization (Illumina) were then washed and 
scanned with the Bead Station 500 System (Illumina).  The 
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signal intensities from the scanner were quantified using 
GenomeStudio Software (Illumina).  Quantile normalization 
in linear models was used to normalize the data. 
Whole genome mRNA expression profiling was 
performed on primary tumors, lymph nodes, metastases 
and CTCs.  Expression data are available at NCBI GEO 
(GSE48496). A class comparison tool within BRB 
ArrayTools (National Cancer Institute, version 4) was used 
to select genes that are differentially expressed between 
the different tissue sites (6 replicates for each group).  The 
values were averaged over replicates of samples and a 
two-sample t test was used to calculate the significance of 
the observations (FDR < 0.05 and p < 0.001). WebGestalt 
(http://genereg.ornl.gov/webgestalt) was used to perform 
KEGG pathway analyses [58].  Finally, to visualize 
expression patterns of specific genes of interest, expression 
values of these genes were adjusted to a median of zero 
and then analyzed with Cluster and TreeView [59]. 
Real-time PCR analysis
Total RNA was isolated from xenograft tissue, FACS 
isolated CTCs, and 2D cultured cells using mirVANATM 
miRNA Isolation Kit (Ambion, Life Technologies, CA) 
according to the manufacturer’s protocol.  Quantitative 
real time PCR (RT-PCR; Step One, Applied Biosystems) 
was used together with TaqMan® Gene Expression Assays 
(Applied Biosystems).  The comparative CT method was 
used to determine relative gene expression for each target 
gene. To normalize for the amount of amplifiable RNA, 
the peptidylprolyl isomerase A (cyclophilin A) gene was 
used as an endogenous control.  All experiments were 
performed in triplicates.
Immunoblotting
Cells grown in monolayer cultures were harvested at 
75% to 85% confluence in lysis buffer [1% Triton X-100, 
150 mmol/L NaCl, 25 mmol/L Tris, 1 mmol/L glycerol 
phosphate,1 mmol/L sodium orthovanadate, 1 mmol/L 
sodium fluoride and protease inhibitor cocktail (Sigma)] 
and were rotated for 30 minutes at 4°C. The lysates were 
centrifuged at 14,000 rpm for 10 min at 4°C to harvest 
supernatants. Protein concentrations were measured 
using the Bio-Rad Bradford protein assay (Bio-Rad 
Laboratories, Hercules, CA). Protein samples were boiled 
for 5 min in Laemmli’s SDS-PAGE sample buffer and 
resolved on 10% SDS-PAGE gels followed by protein 
transfer to nitrocellulose membranes. After blocking, 
anti-SNAIL Ab LS-C161334 (LSBio Inc.) was used 
to investigate the SNAIL knockdown. Species specific 
(Anti-Rabbit) secondary antibody was used for probing, 
and the enhanced chemiluminescence system (Amersham 
Biosciences, Piscataway, NJ) for detection.
Statistics
Statistical analysis was performed using GraphPad 
Prism Software (GraphPad, San Diego, CA). As 
appropriate, raw data or percentages were compared by 
unpaired Student’s t-test or Mann Whitney test.  Tumor 
growth curves in xenografts were analyzed using Two-
Way ANOVA with Bonferroni multiple comparisons. 
Spearman’s rank correlation coefficient was used to 
determine the significance of correlations between two 
continuous variables in a non-parametric fashion.  Statistical 
significance was set at p < 0.05.
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